{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=I-Cell+Disease",
    "query": {
      "condition": "I-Cell Disease"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 3997,
    "total_pages": 400,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=I-Cell+Disease&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:49:49.795Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02553460",
      "title": "Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "ITMHA",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Mitoxantrone",
          "type": "DRUG"
        },
        {
          "name": "Pegaspargase",
          "type": "DRUG"
        },
        {
          "name": "Asparaginase Erwinia Chrysanthemi",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Mercaptopurine",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "365 Days",
        "sex": "ALL",
        "summary": "Up to 365 Days"
      },
      "enrollment_count": 50,
      "start_date": "2016-01-29",
      "completion_date": "2031-10",
      "has_results": true,
      "last_update_posted_date": "2025-12-10",
      "last_synced_at": "2026-05-22T04:49:49.795Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Orange, California • Palo Alto, California + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02553460"
    },
    {
      "nct_id": "NCT00941720",
      "title": "Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma and Plasma Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "autologous hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2009-06-11",
      "completion_date": "2013-02-28",
      "has_results": true,
      "last_update_posted_date": "2020-07-24",
      "last_synced_at": "2026-05-22T04:49:49.795Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00941720"
    },
    {
      "nct_id": "NCT00104923",
      "title": "Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "fenretinide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "California Cancer Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 29,
      "start_date": "2005-02",
      "completion_date": "2017-04",
      "has_results": false,
      "last_update_posted_date": "2017-07-19",
      "last_synced_at": "2026-05-22T04:49:49.795Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Bethesda, Maryland • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Lubbock",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00104923"
    },
    {
      "nct_id": "NCT05176366",
      "title": "Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ulcerative Colitis",
        "Inflammatory Bowel Diseases"
      ],
      "interventions": [
        {
          "name": "ExoFlo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Direct Biologics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 4,
      "start_date": "2022-12-19",
      "completion_date": "2024-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-02-11",
      "last_synced_at": "2026-05-22T04:49:49.795Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • New York, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05176366"
    },
    {
      "nct_id": "NCT00413322",
      "title": "Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tumor"
      ],
      "interventions": [
        {
          "name": "belinostat",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil (5-FU)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Valerio Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2005-09",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2015-07-08",
      "last_synced_at": "2026-05-22T04:49:49.795Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Omaha, Nebraska • Portsmouth, New Hampshire",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Portsmouth",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00413322"
    },
    {
      "nct_id": "NCT00474929",
      "title": "Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "RAD001",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 103,
      "start_date": "2007-08-29",
      "completion_date": "2019-08-08",
      "has_results": true,
      "last_update_posted_date": "2019-08-20",
      "last_synced_at": "2026-05-22T04:49:49.795Z",
      "location_count": 2,
      "location_summary": "Iowa City, Iowa • Rochester, Minnesota",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00474929"
    },
    {
      "nct_id": "NCT00003102",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Ludwig Institute for Cancer Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "1998-11-17",
      "completion_date": "2003-05-27",
      "has_results": true,
      "last_update_posted_date": "2023-10-04",
      "last_synced_at": "2026-05-22T04:49:49.795Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003102"
    },
    {
      "nct_id": "NCT03602157",
      "title": "Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Immune System Diseases",
        "Immunoproliferative Disorders",
        "Lymphatic Diseases",
        "Lymphoproliferative Disorders",
        "Neoplasms",
        "Cutaneous Lymphoma",
        "Cutaneous Anaplastic Large Cell Lymphoma",
        "Mycosis Fungoides",
        "Sezary Syndrome",
        "Lymphomatoid Papulosis",
        "Cutaneous T Cell Lymphoma",
        "Gray Zone Lymphoma"
      ],
      "interventions": [
        {
          "name": "ATLCAR.CD30.CCR4 cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ALTCAR.CD30 cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2018-12-12",
      "completion_date": "2039-11-04",
      "has_results": false,
      "last_update_posted_date": "2026-01-06",
      "last_synced_at": "2026-05-22T04:49:49.795Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03602157"
    },
    {
      "nct_id": "NCT02528357",
      "title": "GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "GSK3174998",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 141,
      "start_date": "2015-09-11",
      "completion_date": "2020-04-29",
      "has_results": true,
      "last_update_posted_date": "2021-05-18",
      "last_synced_at": "2026-05-22T04:49:49.795Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • New York, New York • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02528357"
    },
    {
      "nct_id": "NCT00295867",
      "title": "Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Zoledronic Acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 45,
      "start_date": "2004-11-03",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2020-05-12",
      "last_synced_at": "2026-05-22T04:49:49.795Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00295867"
    }
  ]
}